Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial
J von Pawel, T Larson, S Ou, S Limentani, A Sandler, E Vokes, S Kim, K Liau, P Bycott, A Olszanski, J Schiller · Pneumologie · 2008 · Heft 04
Bibliografische Angaben
Zusammenfassung
Background: A correlation between vascular endothelial growth factor (VEGF), microvessel density, and prognosis has been reported in pts with NSCLC. AG is a specific VEGF receptor (VEGFR) inhibitor with picomolar potency against VEGFR 1, 2 and 3. This is an open-label, multicenter phase II study examining the efficacy and safety of single-agent AG in pts with advanced NSCLC. Methods: Pts with stage IIIB or metastatic NSCLC received AG 5mg BID. Eligibility criteria included measurable disease and ECOG performance status of 0 or 1. A Simon 2-stage minimax design was used with 18 pts in the first stage plus an addi…
